AbbVie Inc (ABBV)vsKazia Therapeutics Ltd ADR (KZIA)
ABBV
AbbVie Inc
$246.12
+0.98%
HEALTHCARE · Cap: $430.82B
KZIA
Kazia Therapeutics Ltd ADR
$12.00
-2.52%
HEALTHCARE · Cap: $139.52M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 3391136% more annual revenue ($64.39B vs $1.90M). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV appears more attractively valued with a PEG of 0.41. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
KZIA
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.12
$95.22 premium
Intrinsic value data unavailable for KZIA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Revenue surging 312.4% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : KZIA
The strongest argument for KZIA centers on Revenue Growth, Debt/Equity. Revenue growth of 312.4% demonstrates continued momentum. PEG of 1.01 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : KZIA
The primary concerns for KZIA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while KZIA is a hypergrowth play — different risk/reward profiles.
KZIA carries more volatility with a beta of 2.15 — expect wider price swings.
KZIA is growing revenue faster at 312.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 35/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Kazia Therapeutics Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?